ArticleMolecular cancer therapeutics2023

Preclinical Evaluation of ON203, A Novel Bioengineered mAb Targeting Oxidized Macrophage Migration Inhibitory Factor as an Anticancer Therapeutic.

Gregor Rossmueller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.